VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
With flu season approaching, the U.S. federal government has earmarked nearly $1 billion for the development of swine flu vaccines.
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Medtronic announced at its annual investor meeting that it has acquired substantially all glucose monitoring technology from Danish company PreciSense.
Sensimed, a Swiss company focused on the development of integrated micro-systems for medical devices, has received the Red Herring 100 Europe 2009 Award.
Pharmaceutical company VIVUS has initiated an open label safety study of the investigational drug avanafil in males with erectile dysfunction.
VentureWire reports that Transcend Medical, a developer of devices to treat glaucoma, has raised $20 million in equity.
Every year, millions of U.S. patients are outfitted with a PICC line, a catheter threaded to the superior vena cava from the arm for the administration of treatments such as antibiotics or chemotherapy.
Copyright © 2025 | WordPress Theme by MH Themes